Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

Medicinal Research Reviews

Volumn 37, Issue 5, 2017, Pages 1186-1225

  Bachurin, Sergey O ^a   Bovina, Elena V ^a   Ustyugov, Aleksey A ^a  

^a INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

AD treatment; Alzheimer's disease; amyloid beta; clinical trial; disease modifying drugs; multitargeting compounds; neurodegenerative disease; proteinopathy; repositioning of old drugs; Tauopathy

Indexed keywords

ADENYLATE CYCLASE INHIBITOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DRUG; ELND 005; ENZYME INHIBITOR; GLUTAMATE RECEPTOR; ION CHANNEL; MONOAMINE OXIDASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RO 63 8695; SAN 61; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; NERVE CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG DEVELOPMENT;

ALZHEIMER DISEASE; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS;

EID: 85019707192     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21434     Document Type: Review

References (212)

1. Skripka-Serry J. The great neuro-pipeline brain drain and why Big Pharma hasn't given up on CNS disorders. 2013. http://www.ddw-online.com/therapeutics/p216813-the-great-neuro-pipeline-brain-drain-(and-why-big-pharma-hasn-t-given-up-on-cns-disorders)-fall-13.html.
2. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 2014;6(4):37.
3. Kukharsky MS, Ovchinnikov RK, Bachurin SO. [Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer's disease]. Zh Nevrol Psikhiatr Im SS Korsakova 2015;115(6):103–114.
4. Nussbaum JM, Seward ME, Bloom GS. Alzheimer disease: A tale of two prions. Prion 2014;7(1):14–19.
5. Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem 2013;13(15):1745–1770.
6. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 2012;65:329–352.
7. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10(9):698–712.
8. Maccioni RB, Farias G, Morales I, Navarrete L. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010;41(3):226–231.
9. Sorbi S. Molecular genetics of Alzheimer's disease. Aging 1993;5(6):417–425.
10. Armstrong RA. What causes Alzheimer's disease? Folia Neuropathol 2013;51(3):169–188.
11. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet 2016;388(10043):505–517.
12. Bradley WG. Alzheimer's disease: Theories of causation. Adv Exp Med Biol 1990;282:31–38.
13. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17(5):1005–1013.
14. Chartier-Harlin MC, Crawford F, Hamandi K, Mullan M, Goate A, Hardy J, Backhovens H, Martin JJ, Broeckhoven CV. Screening for the beta-amyloid precursor protein mutation (APP717: Val—-Ile) in extended pedigrees with early onset Alzheimer's disease. Neurosci Lett 1991;129(1):134–135.
15. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer's disease locus on chromosome 1. Science 1995;269(5226):970–973.
16. Sisodia SS, Kim SH, Thinakaran G. Function and dysfunction of the presenilins. Am J Hum Genet 1999;65(1):7–12.
17. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988;85(11):4051–4055.
18. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 1988;85(13):4884–4888.
19. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. Lancet 2016;15(7):673–684.
20. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis. Appl Pathol 1984;2(6):357–369.
21. Selkoe DJ. Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol 1994;53(5):438–447.
22. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281(2):1205–1214.
23. Walsh DM, Selkoe DJ. A beta oligomers – A decade of discovery. J Neurochem 2007;101(5):1172–1184.
24. Querfurth HW, LaFerla FM. Alzheimer's disease. New Engl J Med 2010;362(4):329–344.
25. Gavrilova SI, Seleznyova ND, Roschina IF, Fedorova YaB. [Early diagnosis of Alzheimer's disease on the pre-dementia stages and its therapy] In Russian. Moscow: Nauchniy mir. 2014; p. 95–124
26. Friedland-Leuner K, Stockburger C, Denzer I, Eckert GP, Muller WE. Mitochondrial dysfunction: Cause and consequence of Alzheimer's disease. Prog Mol Biol Transl Sci 2014;127:183–210.
27. Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res 2015;12(8):712–722.
28. Tipping KW, van Oosten-Hawle P, Hewitt EW, Radford SE. Amyloid fibres: Inert end-stage aggregates or key players in disease? Trends Biochem Sci 2015;40(12):719–727.
29. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. Nat Rev 2016;12(1):15–27.
30. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(2 Suppl 1):S12–18.
31. Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, Love S. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol 2009;256(5):717–720.
32. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease – A unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2(2-3):85–97.
33. Danysz W, Parsons CG. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine – Searching for the connections. Br J Pharmacol 2012;167(2):324–352.
34. Mohandas E, Rajmohan V, Raghunath B. Neurobiology of Alzheimer's disease. Indian J Psychiatry 2009;51(1):55–61.
35. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280(45):37644–37650.
36. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002;156(3):519–529.
37. Laske C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. New Engl J Med 2015;370(15):1459.
38. Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, Talbot JA, Racke MM, Dean RA. Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis 2013;34(4):897–910.
39. Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'Gorman J, Hock C, Nitsch RM, Sandrock A. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study. Alzheimers Dement 2015;11(7):P277.
40. Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, Terwel D, Tanghe A, Bohrmann B. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci 2014;34(35):11621–11630.
41. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol 2014;34 Suppl 1:S74–79.
42. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30(11):1728–1736.
43. Baxalta. Phase III efficacy, safety, and tolerability study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP (NCT02549170). 2012. https://clinicaltrials.gov/ct2/show/NCT02549170.
44. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 2015;85(8):692–700.
45. Hu C, Adedokun O, Ito K, Raje S, Lu M. Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease. J Clin Pharmacol 2015;55(2):221–229.
46. Jarvis LM. The next chapter in treating Alzheimer's. Chem Eng News ACS 2015;93(22):11–15.
47. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of AFFITOPE vaccines for Alzheimer's disease (AD) – from concept to clinical testing. J Nutr Health Aging 2009;13(3):264–267.
48. PR Newswire. Breakthrough in Alzheimer's disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase ii clinical study. 2014. http://www.prnewswire.com/news-releases/breakthrough-in-alzheimers-disease-affiris-halted-clinical-progression-in-alzheimer-patients-upon-treatment-with-ad04-in-a-phase-ii-clinical-study-261788511.html.
49. Schneeberger A, Hendrix S, Ellison N, Bürger V, Dubois B. Additional results from a phase II study to assess the clinical and immunological activity, safety, and tolerability of AFFITOPE ad02 in patients with early Alzheimer's disease (AD). Alzheimer's & Dementia: J Alzheimer's Assoc. 2015;11(7):P276.
50. Hickman DT, Lopez-Deber MP, Ndao DM, Silva AB, Nand D, Pihlgren M, Giriens V, Madani R, St-Pierre A, Karastaneva H, Nagel-Steger L, Willbold D, Riesner D, Nicolau C, Baldus M, Pfeifer A, Muhs A. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 2011;286(16):13966–13976.
51. Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, Soderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis 2015;43(2):575–588.
52. Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007;25(16):3041–3052.
53. United Neuroscience Ltd. Evaluate the safety, tolerability, immunogenicity and efficacy of UB-311 in mild Alzheimer's disease (AD) patients (NCT02551809). 2015. https://clinicaltrials.gov/ct2/show/NCT02551809.
54. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012;32(28):9677–9689.
55. Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr., Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 2013;36(1):14–23.
56. Dodel R, Rominger A, Blennow K, Barkhof F, Wietek S, Haag S, Bartenstein P, Farlow M, Jessen F. A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%,Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04). Alzheimers Dement 2011;7(4):e55–e56.
57. Pradier L, Cohen C, Blanchard V, Debeir T, Barneoud P, Canton T, Menager J, Bohme A, Rooney T, Guillet M, Cameron B, Shi Y, Naimi S, Ravetch J, Claudel S, Alam J. SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA) Alzheimer's & Dementia: J Alzheimer's Assoc. 2013;9(4):P808–P809.
58. Rosen L, Pomfret M, Billinton A, Chessell I, Chessell T, Kugler A, Lindqvist E, McFarlane M, Groves M, Narwal R, Tan K, Tatipalli M, Dudley A. Tolerability and preliminary pharmacodynamics after single doses of MEDI1814, a beta-amyloid 42 (Aß42)-specific antibody, in mild-moderate Alzheimer's disease. J Prevent Alzheimers Dis. 2015;2(4):287.
59. KHK Pharma. A study of single and multiple doses of KHK6640 in subjects with prodromal or mild to moderate Alzheimer's disease (NCT02127476). 2014. https://clinicaltrials.gov/ct2/show/study/NCT02127476.
60. Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, Marleau AM, Movsesyan N, Kiyatkin A, Rasool S, Larsen AK, Madsen PJ, Wegener KM, Ditlevsen DK, Cribbs DH, Pedersen LO, Agadjanyan MG. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: Prelude to a clinical trial. J Neurosci 2013;33(11):4923–4934.
61. Zhou B, Rothlein R, Shen J, Valcarce C, Selmer J, Hanhan M, Kindy MS, Mjalli AMM, Kostura MJ. TTP4000, a soluble fusion protein inhibitor of Receptor for Advanced Glycation End Products (RAGE) is an effective therapy in animal models of Alzheimer?’s disease. The FASEB Journal 2013;27(1 Supplement):803.801.
62. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet 2014;13(3):319–329.
63. Alexander R, Budd S, Russell M, Kugler A, Cebers G, Ye N, Olsson T, Burdette D, Maltby J, Paraskos J, Elsby K, Han D, Goldwater R, Ereshefsky L. AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF amyloid-beta peptides following single- and multiple-dose administration. Neurobiology of Aging 2014;35:S2.
64. Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice. Mol Neurodegener 2015;10:44.
65. Matijevic M, Watanabe H, Sato Y, Bernier F, McGrath S, Burns L, Yamamoto N, Ogo M, Dezso Z, Chow J, Oda Y, Kaplow J, Albala B. A single dose of the beta-secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys. Alzheimers Dement 2015;11(7):P841.
66. Nicolas L, Kammerer K-P, Schaible J, Link J, Kleiner O, Borta A, Podhorna J, Scholpp J. Pharmacokinetics, pharmacodynamics, and safety of the novel bace inhibitor bi1181181 after oral administration of single ascending doses in healthy subjects. Alzheimers Dement 2015;11(7):P740–P741.
67. FORUM Pharmaceuticals. Safety, tolerability, pharmacokinetics of EVP-0962 and effects of EVP-0962 on cerebral spinal fluid amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease (NCT01661673). 2014. https://clinicaltrials.gov/ct2/show/NCT01661673.
68. Navarro D, Castaner R, Fernandez-Forner D. NME digest. Drugs Future 2015;40(10):667.
69. AZTherapies. Safety and efficacy study of ALZT-OP1 in subjects with evidence of early Alzheimer's disease (NCT02547818). 2015. https://clinicaltrials.gov/ct2/show/NCT02547818.
70. Shanghai Green Valley Pharmaceutical. Safety, efficacy and dose titration of sodium oligo-mannurarate capsule on mild to moderate Alzheimer's disease (NCT01453569). 2014. https://clinicaltrials.gov/ct2/show/NCT01453569.
71. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: Target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry 2012;83(9):894–902.
72. Sinha S, Du Z, Maiti P, Klarner FG, Schrader T, Wang C, Bitan G. Comparison of three amyloid assembly inhibitors: The sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem Neurosci 2012;3(6):451–458.
73. Transition Therapeutics. Transition therapeutics announces results of data analysis from ELND005 phase 2/3 clinical study in agitation and aggression in Alzheimer's disease patients. 2015. http://www.transitiontherapeutics.com/media/press_releases/20151015.pdf.
74. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417(6886):254–259.
75. Suhr OB, Lundgren E, Westermark P. Transthyretin amyloidoses: New strategies for therapeutic intervention. Drugs Future 2010;35(4):325.
76. BELLUS. BELLUS Health announces partnership for the development of BLU8499. 2012. http://www.bellushealth.com/English/investors-and-news/press-releases/press-release-details/2012/BELLUS-Health-Announces-Partnership-for-the-Development-of-BLU84991130839/default.aspx.
77. Vartiainen NE, Williams M, Charles ML, Stenius T, Nurmi A, Yrjanheikki J. SAN-61 protects against Ab1-42, OGD and H2O2 in rat mixed cortical cultures and inhibits GSK-3b (Abst. 336.16/L15). Society for Neuroscience Meeting. 2009. Abstract available online: http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=f92bb357-e664-4d76-8539-68c8c1c397f9&mID=2285&mKey=%7b081F7976-E4CD-4F3D-A0AF-E8387992A658%7d&sKey=2d44ed6c-0abc-4592-9d1b-722055d310ef.
78. Hu Q, Cam J, Lake T, Cummings J, Esposito L, Yadon M-C, Snow A. Identification of Exebryl-1 and other novel small molecules as tau protein aggregation inhibitors. Alzheimer's & Dementia: J Alzheimer's Assoc. 2011;7(4):S481.
79. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8(10):783–793.
80. Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-beta, alpha-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 2016;13(1):179–189
81. Novak M. Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimer's & Dementia: J Alzheimer's Assoc. 2009;5(4):P93.
82. Sheridan C. Pivotal trials for beta-secretase inhibitors in Alzheimer's. Nat Biotechnol 2015;33(2):115–116.
83. Riedmann EM. Swiss biotech firm starts first trial of a tau-targeting Alzheimer vaccine. Hum Vacc Immunother 2014;10(3):531.
84. Bristol-Myers Squibb. A randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjects (NCT02294851). 2014. https://clinicaltrials.gov/ct2/show/NCT02294851.
85. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93(20):11213–11218.
86. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 2015;44(2):705–720.
87. Fox P. Cognitive and functional connectivity effects of methylene blue in healthy aging, mild cognitive impairment and Alzheimer's disease (MB2) (NCT02380573). 2015. https://clinicaltrials.gov/ct2/show/NCT02380573.
88. Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther 2015;352(1):110–118.
89. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer's disease. BioMed Res Int 2016;2016:15.
90. Muggia F, Kudlowitz D. Novel taxanes. Anticancer Drugs 2014;25(5):593–598.
91. Ramirez MJ, Lai MK, Tordera RM, Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: Rationale and current status. Drugs 2014;74(7):729–736.
92. Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;13(11):1092–1099.
93. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: A randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011;26(5):536–544.
94. Daripelli S, Bhyrapuneni G, Mudigonda K, Benade V, Ayyanki G, Kamuju V, Ponnamaneni R, Manoharan A, Nirogi R. Novel 5-HT6 antagonist, SUVN-502 potentiates the effects of donepezil on neurochemical and electrophysiological activity in rat hippocampus (Abst. 761.11). Society for Neuroscience Meeting. 2015. Abstract available online: http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=bf2cda8b-19a9-477b-829a-29ea4c5aaa87&mID=3744&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84&sKey=581d50eb-8d87-43d0-ab59-0f253e8c9e30.
95. Tkachenko S, Ivachtchenko A, Khvat A, Okun I, Lavrovsky Y, Salimov R. Discovery and preclinical studies of AVN-322 highly selective and potent 5HT6 antagonist for cognition enhancement in treating neurodegerative diseases. 2009. Abstract available online: http://www.karger.com/ProdukteDB/miscArchiv/NDD_2009_006_s_1/pdf/945.pdf.
96. Kwon S, Rajagopal L, Huang M, Michael E, Meltzer H. RP5063 reverses and prevents sub-chronic phencyclidine-induced declarative memory deficits and increased dopamine efflux in the prefrontal cortex region in C57BL/6J mice (Abst/823.04). Society for Neuroscience Meeting. 2015. Abstract available online: http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=43ca0d8f-ec97-4d1d-b215-94312a182bfb&mID=3744&mKey=d0ff4555-8574-4fbb-b9d4-04eec8ba0c84&sKey=b0f5ac8e-9e1b-453c-be9d-378790a1281e.
97. Thomsen MS, Andreasen JT, Arvaniti M, Kohlmeier KA. Nicotinic acetylcholine receptors in the pathophysiology of Alzheimer's disease: The role of protein-protein interactions in current and future treatment. Curr Pharm Des 2016;22(14):2015–2034.
98. Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2013;96(Pt B):255–262.
99. Othman A, Meier A, Ritchie CW, Florian H, Gault LM, Tang Q. Efficacy and safety of the alpha7 agonist abt-126 as a monotherapy treatment in mild-to-moderate alzheimer's dementia: results of a phase 2b trial. Alzheimers Dement 2014;10(4):P137.
100. Frolich L, Ashwood T, Nilsson J, Eckerwall G. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J Alzheimers Dis 2011;24(2):363–374.
101. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1988;12(4):421–430.
102. Nakamura T, Lipton SA. Protein S-nitrosylation as a therapeutic target for neurodegenerative diseases. Trends Pharmacol Sci 2016;37(1):73–84.
103. Avanir. Avanir Pharmaceuticals announces initiation of phase ii study of AVP-786 for the adjunctive treatment of major depressive disorder. 2014. http://www.prnewswire.com/news-releases/avanir-pharmaceuticals-announces-initiation-of-phase-ii-study-of-avp-786-for-the-adjunctive-treatment-of-major-depressive-disorder-272700931.html.
104. Chumakov I, Nabirotchkin S, Cholet N, Milet A, Boucard A, Toulorge D, Pereira Y, Graudens E, Traore S, Foucquier J, Guedj M, Vial E, Callizot N, Steinschneider R, Maurice T, Bertrand V, Scart-Gres C, Hajj R, Cohen D. Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy. Sci Rep 2015;5:7608.
105. Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, Lane HY. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2014;75(9):678–685.
106. Grigoriev VV, Proshin AN, Kinzirsky AS, Bachurin S. Modern approaches to the design of memory and cognitive function stimulants based on AMPA receptor ligands. Russ Chem Rev 2009;78(5):485.
107. Louis C, Danober L, Carrié I, Dumas N, Albinet K, Llopis K, Roger A, Gandon M-H, Hugot A, Krentner M, Thomas J-Y, Rogez N, Vandesquille M, Krazem A, B´eracoch´ea D, Bertainaanglade V, Drieu la rochelle C, Junges C, Bertrand M, Billiald S, Tordjman C, Cordi A, Lestage P. In vivo pharmacological profile of S47445, a novel positive allosteric modulator of AMPA- type glutamate receptors. Neurodegenerative Diseases 2015;15(s1):p365.
108. Mandavilli A. The amyloid code. Nat Med 2006;12(7):747–751.
109. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011;3(2):16.
110. Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, Kenny RA, Howard R, Murphy C, Kelly J, Adams J, Daly L, Segurado R, Gaynor S, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Wallin A, Borjesson-Hanson A, Molloy W, Tsolaki M, Olde Rikkert M. A European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open 2015;5:e006364 doi:10.1136/bmjopen-2014-006364corr1.
111. Ferguson S, Bishop A, Mouzon B, Phillips J, Crynen G, Reed J, Chaytow H, Mullan M, Mathura V, Mullan M, Crawford F. Time course of inflammatory marker response after TBI (Abst #. 254.07/Z8). Society for Neuroscience Meeting. 2011. Abstract available online: http://www.abstractsonline.com/plan/ViewAbstract.aspx?cKey=85154344-ca2b-494e-a787-e1323f81fc1b&mID=2773&mKey=%7b8334BE29-8911-4991-8C31-32B32DD5E6C8%7d&sKey=d70333de-8bb5-4d9f-8a2c-f5d7e7ea5ef1.
112. Sadek B, Saad A, Sadeq A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behavioural brain research 2016;312:415–430.
113. Panayi F, Sors A, Bert L. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors. Neurodegenerative Diseases 2015;15(s1):p156.
114. Benade VS, Daripelli S, Thentu JB, Manoharan A, Medapati RB, Subramanian R, Mekala VR, Shinde AK, Badange RK, Goyal VK, Pandey SK, Nirogi R. SUVN-G3031, a H3 receptor inverse agonist produces procognitive effects without affecting sleep in preclinical models. Alzheimers Dement 2015;11(7):P475.
115. Yao J, Zhao L, Mao Z, Chen S, Wong KC, To J, Brinton RD. Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor beta-selective phytoSERM treatments. Brain Res 2013;1514:128–141.
116. Rinne JO, Wesnes K, Hänninen J, Murphy M, Riordan H, Rouru J, Group AS. Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer's disease: A randomized, double-blind, proof-of-concept study. J Neurol Sci 2013;333:e322.
117. Lahmy V, Meunier J, Malmstrom S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T. Blockade of Tau hyperphosphorylation and Abeta(1)(-)(4)(2) generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology 2013;38(9):1706–1723.
118. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17(12):1652–1656.
119. Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Hoglinger GU. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Neuropharmacology 2015;95:367–376.
120. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012;109(42):E2895–2903.
121. Xiao R. Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease. Curr Top Med Chem 2016;16(5):565–573.
122. Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, Gerhardt GA, Reed MN. Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. J Neurochem 2015;135(2):381–394.
123. Sugiyama A, Saitoh A, Inagaki M, Oka J, Yamada M. Systemic administration of riluzole enhances recognition memory and facilitates extinction of fear memory in rats. Neuropharmacology 2015;97:322–328.
124. Blasco H, Mavel S, Corcia P, Gordon PH. The glutamate hypothesis in ALS: Pathophysiology and drug development. Curr Med Chem 2014;21(31):3551–3575.
125. Giacobini E. Therapy of Alzheimer disease: Symptomatic or neuroprotective? J Neural Transm 1994;43:211–217.
126. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271(13):985–991.
127. Lane RM, He Y. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimers Dement 2013;9(2):e1–73.
128. Furukawa-Hibi Y, Alkam T, Nitta A, Matsuyama A, Mizoguchi H, Suzuki K, Moussaoui S, Yu QS, Greig NH, Nagai T, Yamada K. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-beta peptide in mice. Behav Brain Res 2011;225(1):222–229.
129. Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 2008;275(4):625–632.
130. Macdonald IR, Rockwood K, Martin E, Darvesh S. Cholinesterase inhibition in Alzheimer's disease: Is specificity the answer? J Alzheimers Dis 2014;42(2):379–384.
131. Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes. J Alzheimers Dis 2013;33(3):547–658.
132. Bhattacharya S, Maelicke A, Montag D. Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice. J Alzheimers Dis 2015;46(1):123–136.
133. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012;13(4):483–494.
134. Webster S, Pallin D. Discovery of UE2343, a potent inhibitor of 11beta-HSD1 for the treatment of Alzheimer's disease. 2015. http://adisinsight.springer.com/drugs/800042157.
135. Astellas Pharma Global Development. A positron emission tomography occupancy study using ligand [11C]AS2471907 and following oral dosing of ASP3662 (NCT02194491). 2015. https://clinicaltrials.gov/ct2/show/NCT02194491.
136. Weinreb O, Badinter F, Amit T, Bar-Am O, Youdim MB. Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice. Neurobiol Aging 2015;36(9):2628–2636.
137. Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL. Platelet aggregation unchanged by lipoprotein-associated phospholipase A(2) inhibition: Results from an in vitro study and two randomized phase I trials. PloS One 2014;9(1):e83094.
138. GlaxoSmithKline. GSK2647544 RD, DDI in healthy young and elderly volunteers (NCT01978327). 2014. https://clinicaltrials.gov/ct2/show/NCT01978327.
139. Rosenbrock H, Marti A, Koros E, Runge F, Fuchs H, Giovannini R, Dorner-Ciossek C. Improving synaptic plasticity and cognitive function in rodents by the novel phosphodiesterase 9A inhibitor bi 409306. Alzheimers Dement 2015;11:P612.
140. NIH. New NIH-funded memory drug moves into Phase 1 clinical study. 2015. http://www.nih.gov/news-events/news-releases/new-nih-funded-memory-drug-moves-into-phase-1-clinical-study.
141. Sun MK, Hongpaisan J, Lim CS, Alkon DL. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile x mice. J Pharmacol Exp Ther 2014;349(3):393–401.
142. Pradal J, Zuluaga MF, Maudens P, Waldburger JM, Seemayer CA, Doelker E, Gabay C, Jordan O, Allemann E. Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system. Eur J Pharm Biopharm 2015;93:110–117.
143. Alam JJ. Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats. J Alzheimers Dis 2015;48(1):219–227.
144. Lues I, Weber F, Meyer A, Bühring U, Hoffmann T, Kühn-Wache K, Manhart S, Heiser U, Pokorny R, Chiesa J, Glund K. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, aВ glutaminyl cyclase inhibitor, in healthy subjects. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2015;1(3):182–195.
145. Takamura Y, Ono K, Matsumoto J, Yamada M, Nishijo H. Effects of the neurotrophic agent T-817MA on oligomeric amyloid-beta-induced deficits in long-term potentiation in the hippocampal CA1 subfield. Neurobiol Aging 2014;35(3):532–536.
146. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Hoglinger GU, Koestler M, Jack CR Jr., Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH. Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet 2014;13(7):676–685.
147. Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport. Neurobiol Dis 2013;56:79–94.
148. Medipost. “NEUROSTEM-AD” the treatment for Alzheimer's disease requested for phase 1.2a clinical trials. 2013. http://www.medi-post.com/2013/06/8254/.
149. Medipost. The safety and the efficacy evaluation of NEUROSTEM®-AD in patients with Alzheimer's disease (NCT01297218). 2012. https://clinicaltrials.gov/ct2/show/NCT01297218.
150. Anand R, Seiberling M, Kamtchoua T, Pokorny R. Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers. Clin Pharmacokinet 2007;46(4):351–358.
151. FGL-L: Treatment of cognition disorders. Drug Data Rep 2006;28(11):1006
152. Eriksdotter-Jönhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, Blennow K, Bogdanovic N, Jelic V, Kadir A, Nordberg A, Sundström E, Wahlund LO, Wall A, Wiberg M, Winblad B, Seiger Å, Almqvist P, Wahlberg L. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33(1):18–28.
153. Jelinek GA, Weiland TJ, Hadgkiss EJ, Marck CH, Pereira N, van der Meer DM. Medication use in a large international sample of people with multiple sclerosis: Associations with quality of life, relapse rate and disability. Neurol Res 2015;37(8):662–673.
154. Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 2015;33(34):4066–4076.
155. Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial. Urol Oncol 2014;32(1):33.e11–37.
156. Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, Inlay MA, Poon WW, Blurton-Jones M. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci USA 2016;113(9):E1316–1325.
157. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989;16(4 Suppl):516–527.
158. Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Exp rev neurother 2017;17(1):17–32
159. Shin JH, Lee YA, Lee JK, Lee YB, Cho W, Im DS, Lee JH, Yun BS, Springer JE, Gwag BJ. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2012;122(5):952–961.
160. GliaCure. Safety, tolerability, and pharmacokinetic study of single ascending doses of GC021109 in healthy subjects (NCT02254369). 2014. https://clinicaltrials.gov/ct2/show/NCT02254369.
161. Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer's disease. Biomed Rep 2016;4(5):519–522.
162. Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, Sharples R, Sharif S, McFarlane B, Raybould R, Thomas R, Passmore P, Perry VH, Holmes C. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 2015;84(21):2161–2168.
163. Lee DS, Choi J, Kim SH, Kim S. Ameliorating effects of HX106N, a water-soluble botanical formulation, on Abeta25-35-induced memory impairment and oxidative stress in mice. Biol Pharm Bull 2014;37(6):954–960.
164. Shen C, Chen L, Jiang L, Lai TY. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Neurosci Lett 2015;600:132–136.
165. SK Chemicals. A confirmatory trial of SK-PC-B70M in mild to moderate Alzheimer's disease (NCT01249196). 2010. https://clinicaltrials.gov/ct2/show/NCT01249196.
166. Yang G, Wang Y, Sun J, Zhang K, Liu J. Ginkgo biloba for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem 2016;16(5):520–528.
167. Whanin Pharmaceutical Company. An efficacy and safety study of INM-176 for the treatment of patients with Alzheimer type dementia (NCT01245530). 2010. https://clinicaltrials.gov/ct2/show/NCT01245530.
168. Farias GA, Guzman-Martinez L, Delgado C, Maccioni RB. Nutraceuticals: A novel concept in prevention and treatment of Alzheimer's disease and related disorders. J Alzheimers Dis 2014;42(2):357–367.
169. Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 2012;18(1):27–33.
170. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 2015;85(16):1383–1391.
171. Zhai P, Xia CL, Tan JH, Li D, Ou TM, Huang SL, Gu LQ, Huang ZS. Syntheses and evaluation of asymmetric curcumin analogues as potential multifunctional agents for the treatment of Alzheimer's disease. Curr Alzheimer Res 2015;12(5):403–414.
172. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2012;12(2):207–214.
173. Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, Irie K, Katsurabayashi S, Mishima K, Nishimura R, Fujiwara M, Iwasaki K. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull 2012;35(12):2141–2147.
174. Accera. AC-1204 26-week long term efficacy response trial with optional open-label ext (NOURISH AD) (NCT01741194). 2012. https://clinicaltrials.gov/ct2/show/NCT01741194.
175. Sun XJ, Zhao L, Zhao N, Pan XL, Fei GQ, Jin LR, Zhong CJ. Benfotiamine prevents increased beta-amyloid production in HEK cells induced by high glucose. Neurosci Bull 2012;28(5):561–566.
176. O'Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P, Lyons T, Page D, Hanna D, Meara JR, Spanswick D, Guo JP, McGeer EG, McGeer PL, Hobson P. Lack of support for bexarotene as a treatment for Alzheimer's disease. Neuropharmacology 2016;100:124–130.
177. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;335(6075):1503–1506.
178. Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K. Tamibarotene: A candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull 2012;35(8):1206–1212.
179. Ormerod AD, Thind CK, Rice SA, Reid IC, Williams JH, McCaffery PJ. Influence of isotretinoin on hippocampal-based learning in human subjects. Psychopharmacology 2012;221(4):667–674.
180. Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G. Retinoids for treatment of Alzheimer's disease. BioFactors 2012;38(2):84–89.
181. Kelley BJ, Glasser S. Cognitive effects of statin medications. CNS Drugs 2014;28(5):411–419.
182. Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, Abe K. Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: Protection by atorvastatin and pitavastatin. Neuroscience 2011;197:358–368.
183. Zhang YY, Fan YC, Wang M, Wang D, Li XH. Atorvastatin attenuates the production of IL-1beta, IL-6, and TNF-alpha in the hippocampus of an amyloid beta1-42-induced rat model of Alzheimer's disease. Clin Interv Aging 2013;8:103–110.
184. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA. Biliverdin reductase-A: A novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 2012;120(1):135–146.
185. Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 2012;32(14):4705–4715.
186. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011;77(6):556–563.
187. Liang T, Li R, Cheng O. Statins for treating Alzheimer's Disease: Truly ineffective? Eur Neurol 2015;73(5-6):360-366.
188. Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 2016;68(1):127–138.
189. Novak V. Memory aid by intranasal insulin in diabetes (MemAID) (MemAID) (NCT02415556). 2015. https://clinicaltrials.gov/ct2/show/NCT02415556.
190. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2015;44(3):897–906.
191. Egefjord L, Gejl M, Moller A, Braendgaard H, Gottrup H, Antropova O, Moller N, Poulsen HE, Gjedde A, Brock B, Rungby J. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease – Protocol for a controlled, randomized double-blinded trial. Danish Med J 2012;59(10):A4519.
192. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2012;4:e612.
193. Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res 2014;11(6):564–573.
194. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011;32(9):1626–1633.
195. Lupin. A randomized, double-blind, placebo-controlled, parallel group, comparative, multicenter, phase 2 clinical study to evaluate efficacy and safety of two doses of LND101001 monotherapy in patients with mild to moderate Alzheimer's disease (EudraCT 2013-001851-11). 2014. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001851-11/GB/.
196. Yaari R, Hake A. Alzheimer's disease clinical trials: Past failures and future opportunities. Clin Investig 2015;5(3):297–309.
197. Merck & Co. Efficacy and safety of MK-7622 as adjunct therapy in participants with Alzheimer's disease (MK-7622-012) (NCT01852110). 2015. https://clinicaltrials.gov/ct2/show/NCT01852110.
198. Garakani A, Murrough JW, Iosifescu DV. Advances in psychopharmacology for anxiety disorders. FOCUS 2014;12(2):152–162.
199. Lavrovsky Y, Ivachtchenko AV, Morozova M, Salimov RM, Kasey V. Preclinical and early clinical studies of AVN-101, a novel balanced molecule for the treatment of Alzheimer's disease. Alzheimers Dement 2010;6(4):S583.
200. Regenera Pharma. A randomized SAD and MAD study evaluating the safety and tolerability of RPh201 in healthy subjects and in adults with Alzheimer's disease (NCT01513967). 2012. https://clinicaltrials.gov/ct2/show/NCT01513967.
201. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study. J Neural Transm 1998;54:301–310.
202. Bukatina EE, Grigor'eva IV, Sokol'chik EI. The effectiveness of amiridin in senile dementia of the Alzheimer's type. Neurosci Behav Physiol 1993;23(1):83–89.
203. Qian ZM, Ke Y. Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? Front Aging Neurosci 2014;6:216
204. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs. Br J Clin Pharmacol 2012;73(4):504–517.
205. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, Kearns I, Kehoe P, Mudher A, Passmore A, Shepherd N, Walsh F, Ballard C. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012;11(11):833–846.
206. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. J Intern Med 2014;275(3):251–283.
207. Iqbal K, Grundke-Iqbal I. Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 2007;64(17):2234–2244.
208. Pal R, Larsen JP, Moller SG. The Potential of Proteomics in Understanding Neurodegeneration. International review of neurobiology 2015;121:25–58
209. Whalen J. Experimental Alzheimer's drug fails in clinical trial. The Wall Street Journal 2016 July 27. http://www.wsj.com/articles/experimental-alzheimers-drug-fails-in-clinical-trial-1469652756.
210. American Academy of Neurology. Women's better verbal memory skills may mask early signs of Alzheimer's. 2016. https://www.aan.com/PressRoom/Home/PressRelease/1496.
211. Begley S. Alzheimer's researchers seethe over years of missteps after latest drug failure. 2016. https://www.statnews.com/2016/07/28/alzheimers-drug-failure/.
212. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: Clinical trials and drug development. Lancet 2010;9(7):702–716.